# The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

> **NCT04405739** · PHASE2 · COMPLETED · sponsor: **Ridgeback Biotherapeutics, LP** · enrollment: 71 (actual)

## Conditions studied

- SARS-CoV 2

## Interventions

- **DRUG:** EIDD-2801
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04405739
- **Lead sponsor:** Ridgeback Biotherapeutics, LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2022-02-21
- **Final completion:** 2022-02-21
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405739, "The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04405739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*